SCHEMBL6242553

SCHEMBL6242553

CC(C)S(=O)(=O)NC1CCCC=C1c1ccc(OCCNS(C)(=O)=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
PKM P14618 2/20 0.37
KDM4E B2RXH2 4/20 0.37
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
DYRK3 O43781 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
CDK1 P06493 1/20 0.35
ROS1 P08922 1/20 0.35
PIM1 P11309 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
CDK2 P24941 1/20 0.35
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6241883 0.94 ALDH1A1 (0.38) ALDH1A1MEN1HTTKMT2AKDM4E
SCHEMBL6242487 0.94 ALDH1A1 (0.46) ALDH1A1MEN1HTTKMT2APKM
SCHEMBL6242856 0.87 ALDH1A1 (0.37) ALDH1A1MEN1HTTKMT2APKM
SCHEMBL6242089 0.86 HRH3 (0.35) ALDH1A1KDM4EHRH3GRIA4
SCHEMBL6242557 0.85 ALDH1A1 (0.43) ALDH1A1MEN1HTTKMT2APKM
SCHEMBL6241136 0.81 GRIA4 (0.37) ALDH1A1GRIA4
SCHEMBL6239993 0.80 MMP2 (0.34) ALDH1A1MEN1KMT2AKDM4EHRH3
SCHEMBL6241888 0.78 CYP1A2 (0.39) ALDH1A1MEN1HTTKMT2AKDM4E
SCHEMBL6242490 0.78 ALDH1A1 (0.47) ALDH1A1MEN1HTTKMT2APKM
SCHEMBL6240728 0.78 GRIA4 (0.39) GSK3BGRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 ALDH1A1 1083/4885MEN1 3961/4885HTT 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.